3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
CNS
1
Conditions
Brain Neoplasms
16
Breast Neoplasms
12
Glioblastoma
5
Neoplasms
3
Gliosarcoma
3
Glioma
3
Ependymoma
3
Oligodendroglioma
2
Neuroma, Acoustic
2
Neurofibromatosis 2
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Central Nervous System Neoplasms
2
Breast Neoplasms, Male
2
Astrocytoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neurilemmoma
1
Medulloblastoma
1
Glioma, Subependymal
1
Familial ependymoma
1
Esophageal Neoplasms
1
Dysgerminoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
23
Bevacizumab
18
Cyclophosphamide
9
Carboplatin
7
Lomustine
6
Irinotecan
6
3-Iodobenzylguanidine
6
Topotecan
5
Radiotherapy
5
Filgrastim
5
Radiosurgery
4
Nivolumab
4
Everolimus
4
Etoposide
4
Drug Therapy
4
Busulfan
4
sonidegib
3
pembrolizumab
3
olaparib
3
fludarabine phosphate
3
fludarabine
3
cemiplimab
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Vincristine
3
Thiotepa
3
Sirolimus
3
Melphalan
3
IL13-PE38
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Lapatinib
×
CNS
×
Clear all
NCT00350727
2013-04-19
VEG102857
GlaxoSmithKline
Phase 2
Completed
75 enrolled
45 charts